Cardio-kidney-metabolic syndrome represents a complex interplay among metabolic disorders, chronic kidney disease (CKD), and cardiovascular disease, resulting in progressive organ damage and a high global disease burden, particularly in patients with type 2 diabetes, in whom morbidity and mortality remain substantial.1 Semaglutide, a human GLP-1 receptor agonist, provides a multi-targeted therapeutic approach by improving glycemic control, reducing blood pressure and body weight, and decreasing systemic inflammation. It also exerts direct renal effects, including natriuresis, favorable hemodynamic changes, improved endothelial function, and inhibition of the renin–angiotensin–aldosterone system. Collectively, these mechanisms contribute to slower CKD progression and reduced cardiovascular risk.2